Last reviewed · How we verify
albuterol plus tiotropium
Albuterol and tiotropium work together as a combination bronchodilator therapy: albuterol provides rapid short-acting relief by stimulating beta-2 adrenergic receptors, while tiotropium provides sustained long-acting bronchodilation by blocking muscarinic M3 receptors.
Albuterol and tiotropium work together as a combination bronchodilator therapy: albuterol provides rapid short-acting relief by stimulating beta-2 adrenergic receptors, while tiotropium provides sustained long-acting bronchodilation by blocking muscarinic M3 receptors. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | albuterol plus tiotropium |
|---|---|
| Also known as | Ventolin® and Spiriva® |
| Sponsor | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy |
| Drug class | Combination bronchodilator (SABA + LAMA) |
| Target | Beta-2 adrenergic receptor (albuterol); M3 muscarinic receptor (tiotropium) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Albuterol is a short-acting beta-2 agonist (SABA) that rapidly relaxes airway smooth muscle for acute symptom relief. Tiotropium is a long-acting muscarinic antagonist (LAMA) that provides sustained 24-hour bronchodilation by blocking acetylcholine-mediated airway constriction. Together, they provide complementary mechanisms for improved airway patency in obstructive airway diseases.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Tremor
- Headache
- Palpitations
- Dry mouth
- Nervousness
Key clinical trials
- Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma (NA)
- Effect on Bronchodilation Response and Ventilation Heterogeneity of Different Inhalation Volumes in COPD
- Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients. (PHASE4)
- A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol. (PHASE3)
- Tiotropium/Salmeterol Inhalation Powder in COPD (PHASE3)
- Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: